Document Detail


CD8+ T-cell activation in HIV-1-infected patients experiencing transient low-level viremia during antiretroviral therapy.
MedLine Citation:
PMID:  23392463     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Transient low-level viremia (TLLV) of 50-400 HIV RNA copies per milliliter is common during antiretroviral therapy, but its pathogenesis, consequences, and optimal management are unclear. Heightened immune activation is associated with detrimental outcomes, including impaired CD4 T-cell reconstitution. Using CD38/HLA-DR expression on CD8 T cells measured in 2 large studies, we determined associations between TLLV and immune activation levels before, during, and after TLLV. We found that TLLV does not significantly change CD8 T-cell activation and that higher CD8 T-cell activation during viral suppression <50 copies per milliliter is associated with a modest increase in the risk of a subsequent TLLV.
Authors:
Babafemi Taiwo; Peter W Hunt; Rajesh T Gandhi; Andrew Ellingson; Matthew McKenna; Jeffrey M Jacobson; Barbara Gripshover; Ronald J Bosch
Related Documents :
25049283 - Invariant nkt cells with chimeric antigen receptor provide a novel platform for safe an...
24648383 - Gremlin 2 promotes differentiation of embryonic stem cells to atrial fate by activation...
3981483 - Hormonal modulation of human natural killer cell activity in vitro.
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural    
Journal Detail:
Title:  Journal of acquired immune deficiency syndromes (1999)     Volume:  63     ISSN:  1944-7884     ISO Abbreviation:  J. Acquir. Immune Defic. Syndr.     Publication Date:  2013 May 
Date Detail:
Created Date:  2013-04-11     Completed Date:  2013-06-24     Revised Date:  2014-09-26    
Medline Journal Info:
Nlm Unique ID:  100892005     Medline TA:  J Acquir Immune Defic Syndr     Country:  United States    
Other Details:
Languages:  eng     Pagination:  101-4     Citation Subset:  IM; X    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Antigens, CD38 / genetics,  metabolism
Antiretroviral Therapy, Highly Active / methods*
CD4 Lymphocyte Count
CD4-Positive T-Lymphocytes / immunology,  virology
CD8-Positive T-Lymphocytes / immunology*
Female
HIV Infections / drug therapy*,  immunology,  virology
HIV-1 / immunology
HLA-DR Antigens / genetics,  metabolism
Humans
Lymphocyte Activation / immunology*
Male
Membrane Glycoproteins / genetics,  metabolism
RNA, Viral / blood
Treatment Outcome
Viremia / drug therapy,  immunology*,  virology
Grant Support
ID/Acronym/Agency:
U01 AI068634/AI/NIAID NIH HHS; U01 AI068636/AI/NIAID NIH HHS; U01AI068636/AI/NIAID NIH HHS; U01AI68634/AI/NIAID NIH HHS; UM1 AI069412/AI/NIAID NIH HHS; UM1 AI069471/AI/NIAID NIH HHS; UM1 AI069496/AI/NIAID NIH HHS
Chemical
Reg. No./Substance:
0/HLA-DR Antigens; 0/Membrane Glycoproteins; 0/RNA, Viral; EC 3.2.2.5/Antigens, CD38; EC 3.2.2.5/CD38 protein, human
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  HIV and recent illicit drug use interact to affect verbal memory in women.
Next Document:  Nevirapine inhibits the anti-HIV activity of CD8+ cells.